Health
Combination immunotherapy benefits subset of patients with advanced prostate cancer – Medical Xpress
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic cast…
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab (anti-CTLA-4) plus nivolumab (anti-PD-1) can generate durable responses in a subset of patients with metastatic castration-resistant prostate cancer (mCRPC), an “immune-cold” cancer that does not typically respond well to immunotherapy.
In a cohort of patients without previous chemotherapy treatment, the overall response rate (ORR) was 25% and median ove…
-
Noosa News22 hours agoBrisbane man charged with arson and attempted murder after violent house fire at Wynnum West
-
Business16 hours ago3 perfect ASX ETFs for beginners
-
Noosa News22 hours agoAI a ‘strategic necessity’ law lecturer says – Proctor
-
Business19 hours agoDown 53% in a year, are Domino’s shares now on sale?